Vertex has done everything an investor could ask for in 2017, including double its market cap to almost $40B.
Vertex Pharmaceuticals Inc., on the brink of a breakthrough that could treat nearly all patients with cystic fibrosis, has done everything an investor could ask for in 2017, including double its market cap to almost $40 billion.
For restless bulls hoping for more, the money gets a little harder to make from here.
News in July that an experimental three-drug cocktail worked better than expected for a stubborn form of the deadly lung disease has helped the stock rise 111 percent in 2017 and made it the best performer in the S&P 500 for most of the year.
